CC BY-NC-ND 4.0 · Journal of Clinical Interventional Radiology ISVIR 2019; 03(03): 162-170
DOI: 10.1055/s-0039-3401304
Review Article
by Indian Society of Vascular and Interventional Radiology

Periprocedural Coagulation Status in Percutaneous Interventions

Soumil Singhal
1   Department of Intervention Radiology and Intervention Oncology, BGS Gleneagles Global Hospital, Kengeri, Bangalore, India
Mangerira Chinnappa Uthappa
1   Department of Intervention Radiology and Intervention Oncology, BGS Gleneagles Global Hospital, Kengeri, Bangalore, India
› Author Affiliations
Further Information

Publication History

received 29 October 2018

accepted after revision 27 May 2019

Publication Date:
02 December 2019 (online)


Hemostasis is a very elaborate process, and its knowledge is essential for every interventional radiologist. Abnormal coagulation parameters are associated with an increased risk of bleeding and require appropriate management. This review aims to briefly discuss the pathophysiology of hemostasis, the role of currently available pharmacological agents affecting hemostasis, and the management of hemostasis during various percutaneous interventional procedures. A preprocedure proforma, when used as a checklist, can reduce procedure-related complications.

  • References

  • 1 Achneck HE, Sileshi B, Parikh A, Milano CA, Welsby IJ, Lawson JH. Pathophysiology of bleeding and clotting in the cardiac surgery patient: from vascular endothelium to circulatory assist device surface. Circulation 2010; 122 (20) 2068-2077
  • 2 Kumar V, Abbas AK, Fausto N, Aster JC. Hemodynamic disorders, thromboembolic disease and shock. In: Robbins and Cotran Pathologic Basis of Disease. 8th ed.. Philadelphia, PA: Saunders Elsevier; 2010: 118-120
  • 3 Triplett DA. Coagulation and bleeding disorders: review and update. Clin Chem 2000; 46 (8 Pt 2) 1260-1269
  • 4 Greinacher A, Selleng K. Thrombocytopenia in the intensive care unit patient. Hematology (Am Soc Hematol Educ Program) 2010; 2010: 135-143
  • 5 O’Connell B, Lee EJ, Schiffer CA. The value of 10-minute posttransfusion platelet counts. Transfusion 1988; 28 (01) 66-67
  • 6 Schiffer CA, Anderson KC, Bennett CL. et al. American Society of Clinical Oncology. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19 (05) 1519-1538
  • 7 Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337 (26) 1861-1869
  • 8 Heal JM, Blumberg N. Optimizing platelet transfusion therapy. Blood Rev 2004; 18 (03) 149-165
  • 9 Weiss HJ, Baumgartner HR, Tschopp TB, Turitto VT, Cohen D. Correction by factor VIII of the impaired platelet adhesion to subendothelium in von Willebrand disease. Blood 1978; 51 (02) 267-279
  • 10 Lethagen S. Desmopressin–a haemostatic drug: state-of-the-art review. Eur J Anaesthesiol Suppl 1997; 14: 1-9
  • 11 Hyers TM, Agnelli G, Hull RD. et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119 (Suppl. 01) 176S-193S
  • 12 Douketis JD, Berger PB, Dunn AS. et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl. 06) 299S-339S
  • 13 O’Shaughnessy DF, Atterbury C, Bolton Maggs P. et al. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126 (01) 11-28
  • 14 Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev 2007; 21 (01) 37-48
  • 15 Levi M, Peters M, Büller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33 (04) 883-890
  • 16 Kitchens CS. To bleed or not to bleed? Is that the question for the PTT?. J Thromb Haemost 2005; 3 (12) 2607-2611
  • 17 Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (03) Suppl 204S-233S
  • 18 McAvoy TJ. The biologic half-life of heparin. Clin Pharmacol Ther 1979; 25 (03) 372-379
  • 19 Butterworth J, Lin YA, Prielipp R, Bennett J, James R. The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. Anesth Analg 2002; 94 (03) 514-522
  • 20 Brooks JC. Noncardiogenic pulmonary edema immediately following rapid protamine administration. Ann Pharmacother 1999; 33 (09) 927-930
  • 21 Wright SJ, Murray WB, Hampton WA, Hargovan H. Calculating the protamine-heparin reversal ratio: a pilot study investigating a new method. J Cardiothorac Vasc Anesth 1993; 7 (04) 416-421
  • 22 Malloy PC, Grassi CJ, Kundu S. et al. Standards of Practice Committee with Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Endorsement. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol 2009; 20 (Suppl. 07) S240-S249
  • 23 Massonnet-Castel S, Pelissier E, Bara L. et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis 1986; 16 (02) 139-146
  • 24 Vavra KA, Lutz MF, Smythe MA. Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants. Ann Pharmacother 2010; 44 (04) 718-726
  • 25 Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010; 30 (10) 1885-1889
  • 26 Weitz JI. New oral anticoagulants in development. Thromb Haemost 2010; 103 (01) 62-70
  • 27 McMahon BJ, Kwaan HC. The new or non-vitamin K antagonist oral anticoagulants: what have we learned since their debut. Semin Thromb Hemost 2015; 41 (02) 188-194
  • 28 Palladino M, Merli G, Thomson L. Evaluation of the oral direct factor Xa inhibitor - betrixaban. Expert Opin Investig Drugs 2013; 22 (11) 1465-1472
  • 29 Liesenfeld KH, Lehr T, Dansirikul C. et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011; 9 (11) 2168-2175
  • 30 Krishnamoorthy A, Sherwood MW, Lopes RD, Becker RC. The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials. Am Heart J 2015; 169 (03) 315-322
  • 31 Glund S, Moschetti V, Norris S. et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015; 113 (05) 943-951
  • 32 Glund S, Stangier J, Schmohl M. et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015; 386 (9994) 680-690
  • 33 Pollack Jr CV. Reilly PA, Bernstein R. et al. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 2015; 114 (01) 198-205
  • 34 Pollack Jr CV. Reilly PA, Eikelboom J. et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373 (06) 511-520
  • 35 Hollenbach S, Lu G, DeGuzman F. et al. Abstract 14657: Andexanet-alfa and PER977 (Arapazine) correct blood loss in a rabbit liver laceration model - only andexanet reverses markers of fXa-mediated anticoagulation. Circulation 2014; 130 (02) A14657
  • 36 Antiplatelet Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, MI, and stroke in high-risk patients. BMJ 2002; 324: 71-86
  • 37 Peters RJ, Mehta SR, Fox KA. et al. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108 (14) 1682-1687
  • 38 Leithäuser B, Zielske D, Seyfert UT, Jung F. Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel. Clin Hemorheol Microcirc 2008; 39 (01) (04) 293-302
  • 39 Bijsterveld NR, Moons AH, Boekholdt SM. et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106 (20) 2550-2554
  • 40 Reiter RA, Mayr F, Blazicek H. et al. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003; 102 (13) 4594-4599
  • 41 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365 (02) 147-156
  • 42 Northup PG, Sundaram V, Fallon MB. et al. Coagulation in Liver Disease Group. Hypercoagulation and thrombophilia in liver disease. J Thromb Haemost 2008; 6 (01) 2-9
  • 43 Lisman T, Bongers TN, Adelmeijer J. et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44 (01) 53-61
  • 44 Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98 (09) 2730-2735
  • 45 Tripodi A, Primignani M, Chantarangkul V. et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006; 44 (02) 440-445
  • 46 Tripodi A, Primignani M, Chantarangkul V. et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009; 137 (06) 2105-2111
  • 47 Tripodi A, Salerno F, Chantarangkul V. et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41 (03) 553-558
  • 48 Salooja N, Perry DJ. Thrombelastography. Blood Coagul Fibrinolysis 2001; 12 (05) 327-337
  • 49 Tripodi A, Primignani M, Chantarangkul V. et al. The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thromb Res 2009; 124 (01) 132-136
  • 50 Viola F, Kramer MD, Lawrence MB, Oberhauser JP, Walker WF. Sonorheometry: a noncontact method for the dynamic assessment of thrombosis. Ann Biomed Eng 2004; 32 (05) 696-705
  • 51 Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984; 74 (09) 979-983
  • 52 Patel IJ, Davidson JC, Nikolic B. et al. Standards of Practice Committee, with Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Endorsement; Standards of Practice Committee of the Society of Interventional Radiology. Addendum of newer anticoagulants to the SIR consensus guideline. J Vasc Interv Radiol 2013; 24 (05) 641-645